CAS Number: 1977495-97-8
Trilaciclib (G1T28) Hydrochloride is a small molecule inhibitor of the CDK4/6 kinases that play a critical role in cell cycle regulation and are overexpressed in many types of cancer. Trilaciclib works by selectively blocking CDK4/6 activity, which leads to a temporary arrest of cell division in rapidly dividing cancer cells.
Trilaciclib has been studied as a potential treatment for cancer in combination with chemotherapy. By temporarily inhibiting CDK4/6 activity, trilaciclib may help protect normal cells, such as immune cells, from chemotherapy-induced cell death, which can lead to an improvement in treatment response and reduced side effects. Additionally, trilaciclib may enhance the effectiveness of chemotherapy by synergistically suppressing the growth of cancer cells through the combination of chemotherapy and CDK4/6 inhibition.
Trilaciclib Hydrochloride is an investigational medication and is not yet approved for any indication by regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
However, it has been studied as a potential treatment for patients with small cell lung cancer (SCLC) undergoing chemotherapy. In clinical trials, trilaciclib hydrochloride was given in combination with chemotherapy to help preserve white blood cells and reduce the severity and duration of chemotherapy-induced neutropenia, which is a common side effect of chemotherapy that can lead to infections and other complications.
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Trilaciclib Hydrochloride API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Trilaciclib Hydrochloride API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Please fill in the following form for API Requirement & we'll get back to you shortly
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.